MacroGenics to Participate in Upcoming Investor Conference
Rhea-AI Summary
MacroGenics (Nasdaq: MGNX) has announced its participation in the 7th Annual Evercore HealthCONx conference in Coral Gables, FL. The company's President and CEO, Scott Koenig, M.D., Ph.D., will engage in a fireside chat on December 4, 2024, at 7:30am ET, alongside one-on-one meetings.
The presentation will be available via webcast in the Investor Relations section of MacroGenics' website, with an archived replay accessible for 30 days. MacroGenics specializes in developing and commercializing innovative monoclonal antibody-based therapeutics for cancer treatment.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, MGNX declined 6.78%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
ROCKVILLE, MD, Dec. 02, 2024 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conference this month:
- 7th Annual Evercore HealthCONx (Coral Gables, FL). MacroGenics’ President and Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Wednesday, December 4, 2024, at 7:30am ET. MacroGenics’ management will also participate in one-on-one meetings.
A webcast of the above presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of this webcast on its website for 30 days.
About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
###
FAQ
When is MacroGenics (MGNX) presenting at the Evercore HealthCONx conference 2024?
Where can I watch MacroGenics (MGNX) Evercore HealthCONx 2024 presentation?
How long will MacroGenics (MGNX) 2024 Evercore presentation replay be available?
What type of meetings will MacroGenics (MGNX) conduct at Evercore HealthCONx 2024?
